Ranbaxy Inc.

Pharma company files three antiretrovirals with the U.S. FDA

Published in Drug Law Weekly, February 8th, 2005

Ranbaxy Laboratories Limited (Ranbaxy) announced that the company has so far made three filings of its antiretrovirals (ARVs) to the U.S. Food and Drug Administration (FDA) for its approval under the expedited review process of the President's Emergency Plan for AIDS Relief (PEPFAR).

Earlier, in July 2004, Ranbaxy had said that the company would make its first ARV filing with the U.S. FDA under the PEPFAR, by the end of 2004. Ranbaxy has met this expectation and has filed two additional ARVs with the U.S. FDA after its first ARV filing in October 2004.

Speaking on the occasion, Dr. Brian W. Tempest, CEO and managing director of Ranbaxy, said, "We are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry